rg7388 profile

RG7388: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	53358942
CHEMBL ID	2402737
SCHEMBL ID	442856
MeSH ID	M0592199

Synonym
4-{[(2r,3s,4r,5s)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid
TVTXCJFHQKSQQM-LJQIRTBHSA-N
4-((2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzoic acid
S7205
idasanutlin [usan]
idasanutlin [who-dd]
idasanutlin [inn]
1229705-06-9
idasanutlin
idasanutlin [usan:inn]
rg7388
ro-5503781
rg-7388
qsq883v35u ,
benzoic acid, 4-((((2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-
ro5503781
unii-qsq883v35u
bdbm50437206
chembl2402737 ,
HY-15676
CS-1473
SCHEMBL442856
benzoic acid, 4-[[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-
AC-32968
AKOS026674115
5-[9-isopropyl-8-methyl-2-(4-morpholinyl)-9h-purin-6-yl]-2-pyrimidinamine
J-690081
EX-A831
rg-7388;idasanutlin
ro 5503781
4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid
idasanutlin (rg-7388)
DB12325
NCGC00378976-08
idasanutlin (rg7388)
4-((2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzoic acid.
mfcd26142931
rg-7388;rg 7388;rg7388; ro5503781; ro-5503781; ro 5503781
BCP11659
idasanutlin (usan/inn)
D11219
AMY1857
4-[[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxybenzoic acid
CCG-270248
nsc-779404
nsc779404
Q27287480
A857397
BP-25380
DTXSID001025954
4-((((2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-benzoic acid
4-[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-amido]-3-methoxybenzoic acid
EN300-26181975

Excerpt	Reference	Relevance
"RG7388 did not enhance XRT-induced local skin toxicity."	( Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Bondra, K; Chronowski, C; Houghton, PJ; Kurmasheva, RT; Leasure, J; Middleton, S; Mo, X; Phelps, D; Seum, S; Wang, D, 2015)	1.45

Excerpt	Reference	Relevance
"The RG7388 treatment was able to induce cell death by elevating p21"	( Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21 Natarajan, U; Radhakrishnan, V; Rasappan, P; Rathinavelu, A; Samuel, S; Venkatesan, T, 2019)	1.32

Excerpt	Reference	Relevance
"A total of 69 patients who have both idasanutlin pharmacokinetic data and UGT genotyping data were analyzed for association."	( Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients. Ou Yang, TH; So, WV; Yang, X; Zhi, J, 2019)	0.51
" Physiologically-based pharmacokinetic models of idasanutlin and M4 have been established to simulate perpetrator and victim DDI scenarios and to evaluate whether further DDI studies in oncology patients are necessary."	( Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions. Cleary, Y; Fowler, S; Parrott, N; Tuerck, D; Umehara, K, 2022)	0.72

Excerpt	Reference	Relevance
" This study assessed the efficacy of RG7388 as a single-agent and in combination with chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma cell lines."	( Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Chen, L; Lunec, J; Middleton, SA; Newell, DR; Nichols, GL; Rousseau, RF; Tweddle, DA, 2015)	0.94
"To investigate whether the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) combined with the selective MDM2 antagonist idasanutlin (RG7388) offers superior efficacy to monotherapy in treating B-lymphoid malignancies in preclinical models."	( Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). Bacac, M; Dangl, M; Friess, T; Herter, S; Herting, F; Klein, C; Muth, G; Sulcova, J; Umana, P, 2016)	0.83
" This is the first study to evaluate the in vivo efficacy of the intravenous idasanutlin prodrug, RO6839921 (RG7775), both alone and in combination with temozolomide in TP53 wt orthotopic neuroblastoma models."	( Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Berry, P; Bonner, J; Chen, L; Daga, A; Kirk, C; Lunec, J; Newell, DR; Pastorino, F; Ponzoni, M; Thomas, HD; Tweddle, DA; Veal, GJ; Wood, KM; Zhao, Y, 2019)	0.51
" For safety reasons, it cannot be given in healthy volunteers for drug-drug interaction (DDI) explorations."	( Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions. Cleary, Y; Fowler, S; Parrott, N; Tuerck, D; Umehara, K, 2022)	0.72

Excerpt	Reference	Relevance
"This was an open-label, single-dose, crossover clinical pharmacology study investigating the effects of strong CYP3A4 inhibition with posaconazole (Part 1), two new oral formulations (Part 2), as well as high-energy/high-fat and low-energy/low-fat meals (Part 3) on the relative bioavailability of idasanutlin."	( Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J, 2018)	0.48

Excerpt	Relevance	Reference
"Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor."	( Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A, 2014)	0.4
"A pharmacokinetic-pharmacodynamic (PKPD) model was developed on the basis of preclinical data to determine alternative dosing schedule requirements for optimal RG7388-induced antitumor activity."	( Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A, 2014)	0.6
" In initial efficacy testing, daily dosing at 30 mg/kg and twice a week dosing at 50 mg/kg of RG7388 were statistically equivalent in our tumor model."	( Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A, 2014)	0.62
" Alternative dosing regimens and combination with other targeted agents are needed to achieve successful development of nutlin in the clinical setting."	( Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. Chaire, V; Chibon, F; Coindre, JM; Hostein, I; Italiano, A; Lagarde, P; Laroche, A; Lesluyes, T; Lucchesi, C; Neuville, A; Tran-Cong, K, 2015)	0.42
" To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors."	( Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J, 2018)	0.48
" Overall, RO6839921 had a favourable pharmacokinetic profile consistent with intermittent dosing and was well tolerated alone and in combination."	( Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Berry, P; Bonner, J; Chen, L; Daga, A; Kirk, C; Lunec, J; Newell, DR; Pastorino, F; Ponzoni, M; Thomas, HD; Tweddle, DA; Veal, GJ; Wood, KM; Zhao, Y, 2019)	0.51
" Methods Patients were evaluated on a 5-day dosing schedule every 28 days."	( A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Abdul Razak, AR; Blotner, S; Chen, LC; Gore, L; Higgins, B; Miller, WH; Uy, GL; Young, AM, 2020)	0.56
" Dose-limiting toxicities were nausea/vomiting and myelosuppression; myelosuppression was more frequent with QD dosing and associated with pharmacokinetic exposure."	( Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. Bang, YJ; Blay, JY; Blotner, S; Chen, LC; Gietema, JA; Higgins, B; Hirte, HW; Italiano, A; Jamois, C; Mileshkin, LR; Miller, WH; Nichols, GL; Petry, C; Schmitt, C; Siu, LL; Yang, QJ, 2021)	0.62
" Overall, the idasanutlin dosing regimen showed clinical activity and rapidly reduced JAK2 allele burden in patients with HU-resistant/- intolerant PV but was associated with low-grade gastrointestinal toxicity, leading to poor long-term tolerability."	( The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Bellini, M; Burbury, K; El-Galaly, TC; Gerds, A; Gupta, V; Higgins, B; Huw, LY; Jamois, C; Katakam, S; Kovic, B; Maffioli, M; Mascarenhas, J; Mesa, R; Palmer, J; Passamonti, F; Ross, DM; Vannucchi, AM; Wonde, K; Yacoub, A, 2022)	0.72
" Two-dimensional dose escalation (DE, n = 50) was performed for venetoclax daily with idasanutlin on days 1 to 5 in 28-day cycles, followed by dosing schedule optimization (n = 6) to evaluate reduced venetoclax schedules (21-/14-day dosing)."	( Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Andreeff, M; Assouline, S; Brandwein, JM; Dail, M; Daver, NG; Fenaux, P; Garcia, JS; Green, C; Hong, WJ; Huang, W; Jonas, BA; Kelly, KR; Konopleva, MY; Martinelli, G; Olin, RL; Onishi, M; Ott, MG; Paolini, S; Pigneux, A; Pollyea, DA; Powell, BL; Roboz, GJ; Tafuri, A; Vey, N; Visani, G; Wang, J; Yee, KWL, 2023)	0.91
" We developed a triple chemotherapy (CAV: cyclophosphamide, doxorubicin, and vincristine) in vivo dosing schedule and applied this to both neuroblastoma genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX)."	( Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. Barker, K; Bellini, A; Bhalshankar, J; Calton, E; Carcaboso, AM; Che, H; Chen, L; Chesler, L; Decaudin, D; Del Nery, E; Delattre, O; Dhariwal, S; Gao, Q; Geoerger, B; George, SL; Gestraud, P; Goodman, A; Gorrini, C; Hutchinson, JC; Iddir, Y; Jamin, Y; Janoueix-Lerosey, I; Jiménez, I; Marques Da Costa, ME; Martins Da Costa, B; Nemati, F; Pierre-Eugène, C; Poon, E; Saberi-Ansari, E; Saint-Charles, A; Schleiermacher, G; Shrestha, S; Surdez, D; Tucker, ER; Tweddle, DA, 2023)	0.91

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	23.3617	0.0052	9.4661	32.9993	AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	13.4504	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	22.8506	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cellular tumor antigen p53	Homo sapiens (human)	IC50 (µMol)	0.0095	0.0006	0.8850	8.2000	AID1182106; AID1182107
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	IC50 (µMol)	0.0077	0.0006	0.3582	10.0000	AID1182106; AID1182107; AID1555896; AID759660
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	Kd	0.0050	0.0000	0.2585	1.0000	AID1075196; AID1807821
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein polyubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
blood vessel development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
blood vessel remodeling	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of heart rate	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
atrioventricular valve morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocardial cushion morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ventricular septum development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
atrial septum development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
apoptotic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
traversing start control point of mitotic cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of cell population proliferation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to xenobiotic stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to toxic substance	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to iron ion	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of gene expression	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of protein processing	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of neuron projection development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein ubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein sumoylation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein destabilization	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to magnesium ion	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein localization to nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to cocaine	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
establishment of protein localization	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to ether	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of DNA-templated transcription	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of mitotic cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to antibiotic	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of protein export from nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to steroid hormone	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of muscle cell differentiation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
proteolysis involved in protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein autoubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cardiac septum morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex assembly	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to hydrogen peroxide	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to vitamin B1	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to alkaloid	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to growth factor stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to peptide hormone stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to estrogen stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to hypoxia	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to gamma radiation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to UV-C	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
fibroblast activation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to actinomycin D	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of signal transduction by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to formaldehyde	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migration	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
amyloid fibril formation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to water-immersion restraint stress	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of apoptotic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of gene expression	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-protein transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
5S rRNA binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
zinc ion binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
SUMO transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
enzyme binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
receptor serine/threonine kinase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
identical protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
peroxisome proliferator activated receptor binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ribonucleoprotein complex binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
NEDD8 ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
disordered domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
nuclear body	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleolus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytosol	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
plasma membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
transcription repressor complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocytic vesicle membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay ID	Title	Year	Journal	Article
AID1483357	Inhibition of p53-MDM2 interaction in human U2OS cells assessed as p53 accumulation at 1 uM after 7 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID1182123	Oral bioavailability in C57 mouse at 50 mg/kg	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID759673	Cell cycle arrest in human SJSA1 cells assessed as accumulation at G2/M phase after 24 hrs	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1182120	Cmax in C57 mouse at 50 mg/kg, po	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID1075195	Antiproliferative activity against human SJSA1 cells assessed as inhibition of EdU incorporation after 1 hr by Click-iT EdU HCS assay in presence of 10% human serum	2014	Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4	Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
AID759675	Cell cycle arrest in human SJSA1 cells assessed as accumulation at G1 phase after 24 hrs	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1483352	Inhibition of p53-MDM2 interaction in human HCT116 cells assessed as p53 activation by measuring increase in MDM2 expression at 1 uM after 7 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID1483334	Inhibition of p53-MDM2 interaction in human U2OS cells assessed as p53 activation by measuring increase in MDM2 expression at 1 uM after 7 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID1807821	Binding affinity to HDM2 (unknown origin)	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of
AID759670	Antitumor activity against human SJSA1 cells xenografted in nude mouse assessed as tumor growth inhibition at 25 mg/kg, po after 2 weeks relative to control	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1483347	Cell cycle arrest in wild type p53 expressing human U2OS cells assessed as increase in accumulation at G1 phase at 1 uM after 24 hrs by propidium iodide-based FACS analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID1483335	Inhibition of p53-MDM2 interaction in human U2OS cells assessed as p53 activation by measuring increase in p21 expression at 1 uM after 24 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID759643	Oral bioavailability in C57 mouse at 50 mg/kg	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1182119	AUC in C57 mouse at 50 mg/kg, po	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID1483359	Induction of human N-terminal MDM2 (1 to 125 residues) dimerization expressed in Escherichia coli BL21 (DE3) by 1H NMR spectroscopic method	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID759652	Cmax in C57 mouse at 50 mg/kg, po	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759653	AUC in C57 mouse at 50 mg/kg, po	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1483358	Induction of human N-terminal MDM2 (1 to 118 residues) dimerization expressed in Escherichia coli BL21 (DE3) by 1H NMR spectroscopic method	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID759667	AUC in nude mouse xenografted with human SJSA1 cells at 25 mg/kg, po	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759666	AUC in nude mouse xenografted with human SJSA1 cells at 12.5 mg/kg, po	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759661	Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as growth inhibition by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759647	Apparent terminal half-life in C57 mouse at 5 mg/kg, iv	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759658	Cytotoxicity against human MDA-MB-435 cells expressing p53 mutant assessed as growth inhibition by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1483348	Inhibition of p53-MDM2 interaction in human U2OS cells assessed as p53 activation by measuring p21 accumulation at 1 uM after 7 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID1483360	Induction of human N-terminal MDM2 (18 to 125 residues) dimerization expressed in Escherichia coli BL21 (DE3) by 1H NMR spectroscopic method	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID1182113	Clearance in human liver microsomes at 1 mM preincubated for 5 mins in presence of NADPH by LC-MS/MS method	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID759672	Induction of apoptosis in human SJSA1 cells after 48 hrs by annexin V staining assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759660	Binding affinity to GST-tagged MDM2 (unknown origin) assessed as inhibition of interaction with p53 after 1 hr by HTRF assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759662	Cytotoxicity against human RKO cells expressing wild type p53 assessed as growth inhibition by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1075196	Binding affinity to human MDM2 by by Surface Plasmon Resonace (SPR) spectroscopy binding assay	2014	Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4	Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
AID1182117	Apparent terminal half life in C57 mouse at 5 mg/kg, iv	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID759663	Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as growth inhibition by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1182116	Total plasma clearance in C57 mouse at 5 mg/kg, iv	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID1483346	Cell cycle arrest in wild type p53 expressing human U2OS cells assessed as decrease in accumulation at S phase at 1 uM after 24 hrs by propidium iodide-based FACS analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID759656	Clearance in human liver microsomes at 1 mM by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1182107	Inhibition of p53-MDM2 (unknown origin) interaction using 0.02% BSA buffer after 1 hr by HTRF assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID1555896	Inhibition of MDM2 (unknown origin)	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Development of selective small molecule MDM2 degraders based on nutlin.
AID1182106	Inhibition of p53-MDM2 (unknown origin) interaction using 0.2% BSA buffer after 1 hr by HTRF assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
AID1129365	Cytotoxicity against human SJSA1 cells assessed as growth inhibition after 16 hrs by EdU incorporation assay in presence of 10% human serum	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
AID759649	Total plasma clearance in C57 mouse at 5 mg/kg, iv	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759674	Inhibition of MDM2 in human SJSA1 cells assessed as induction of p53 stabilization after 20 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID759671	Antitumor activity against human SJSA1 cells xenografted in nude mouse assessed as tumor growth inhibition at 12.5 mg/kg, po after 2 weeks relative to control	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1483353	Inhibition of p53-MDM2 interaction in human HCT116 cells assessed as p53 activation by measuring increase in p21 expression at 1 uM after 24 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
AID759659	Cytotoxicity against human SW480 cells expressing p53 mutant assessed as growth inhibition by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
AID1347172	Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170	Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	44 (63.77)	24.3611
2020's	25 (36.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (14.49%)	5.53%
Reviews	5 (7.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	54 (78.26%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
imidazole imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.	2.11	1	0	imidazole
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.1	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
hydroxyurea [no description available]	6.06	2	1	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
letrozole [no description available]	2.17	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	7.25	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
4-aminobenzoic acid para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.. 4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.	13.38	55	9	aminobenzoate; aromatic amino-acid anion	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.59	2	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide [no description available]	2.66	2	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
cytarabine [no description available]	5.63	2	2	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	3.51	1	0	quinuclidines; saturated organic heterobicyclic parent
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	3.31	1	0	diazine; pyrazines	Daphnia magna metabolite
hydrazine diamine : Any polyamine that contains two amino groups.	3.31	1	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.31	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	4.22	4	0
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.69	2	0	1,2,3-triazole
bendamustine hydrochloride [no description available]	2.31	1	0
lenalidomide [no description available]	3.31	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
2-oxindole 2-oxindole: RN given refers to parent cpd; structure. indolin-2-one : An indolinone carrying an oxo group at position 2.	3.21	1	0	gamma-lactam; indolinone
decitabine [no description available]	3.31	1	0	2'-deoxyribonucleoside
posaconazole [no description available]	2.17	1	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.15	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
palbociclib [no description available]	2.15	1	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	3.39	6	0	stilbenoid
trametinib [no description available]	7.21	1	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
nutlin-3b [no description available]	2.15	1	0	Nutlin; piperazinone	anticoronaviral agent
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.15	1	0	benzazepine
navitoclax [no description available]	2.6	1	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene [no description available]	2.17	1	0	BODIPY compound
incb-018424 [no description available]	3.27	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	3.31	1	0	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	5	7	1	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
apr-246 eprenetapopt: works in tandem with cisplatin to cause apoptosis of tumor cells; structure in first source	3.51	1	0
sar405838 SAR405838: an inhibitor of the interaction of MDM2 and p53; has antineoplastic activity; structure in first source	4.35	5	0
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.17	1	0	benzenes; hydroxycoumarin; methyl ketone
rg7112 [no description available]	4.6	7	0
amg 232 [no description available]	2.81	3	0
gsk2830371 GSK2830371: inhibits Wip1 phosphatase; structure in first source	2.55	2	0
selinexor selinexor: inhibits karyopherin XPO1	3.31	1	0
pf-06463922 lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein. lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.	2.6	1	0	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
enasidenib [no description available]	3.31	1	0	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
pp242 torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.6	1	0	aromatic amine; biaryl; hydroxyindoles; phenols; primary amino compound; pyrazolopyrimidine	antineoplastic agent; mTOR inhibitor
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.21	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Bone Cancer [description not available]	0	2.5	2	0
Osteogenic Sarcoma [description not available]	0	2.5	2	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.5	2	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	2.5	2	0
Benign Neoplasms [description not available]	0	9.39	12	4
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	11.39	12	4
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.29	5	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Brain Stem Neoplasms, Primary [description not available]	0	2.31	1	0
DIPG Brain Tumors [description not available]	0	2.31	1	0
Diffuse Intrinsic Pontine Glioma A rare, aggressive brain tumor that forms in the GLIAL CELLS in the PONS.	0	2.31	1	0
Brain Stem Neoplasms Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.	0	2.31	1	0
Erythremia [description not available]	0	6.37	4	1
Enlarged Spleen [description not available]	0	4.72	1	1
Emesis [description not available]	0	4.72	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	4.72	1	1
Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.	1	8.37	4	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	4.72	1	1
Acute Myelogenous Leukemia [description not available]	0	9.01	10	5
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1	11.01	10	5
Cancer of Lung [description not available]	0	2.61	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.61	2	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	8.67	8	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	3.01	2	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	0	3.01	2	0
Epithelial Ovarian Cancer [description not available]	0	2.6	1	0
Cancer of Ovary [description not available]	0	2.93	3	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	0	2.6	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.93	3	0
Adenocarcinoma, Clear Cell An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)	0	2.6	1	0
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	0	2.6	1	0
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	0	2.6	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.21	1	0
Invasiveness, Neoplasm [description not available]	0	2.21	1	0
Recrudescence [description not available]	0	2.25	1	0
Benign Neoplasms, Brain [description not available]	0	2.58	2	0
Astrocytoma, Grade IV [description not available]	0	2.66	2	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.58	2	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	1	9.66	2	0
Leukemia, Lymphocytic, Chronic, T Cell [description not available]	0	2.31	1	0
Leukemia, Prolymphocytic, T-Cell A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.	0	2.31	1	0
Atypical Lipomatous Tumor [description not available]	0	2.15	1	0
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	0	2.15	1	0
Hematologic Malignancies [description not available]	0	3.06	1	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	3.06	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	2.17	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	1	4.17	1	0
Malignant Melanoma [description not available]	0	2.57	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.57	2	0
Dysplastic Nevus Syndrome, Hereditary [description not available]	0	2.17	1	0
Cancer of Skin [description not available]	0	2.17	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	2.17	1	0
Granulocytic Leukemia [description not available]	0	3.56	1	1
Electrocardiogram QT Prolonged [description not available]	0	3.56	1	1
Acute Disease Disease having a short and relatively severe course.	0	3.56	1	1
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	3.56	1	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	0	3.56	1	1
Breast Cancer [description not available]	0	2.59	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1	4.59	2	0
Cancer of Prostate [description not available]	0	2.21	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.21	1	0
Minimal Disease, Residual [description not available]	0	3.12	1	0
Local Neoplasm Recurrence [description not available]	0	2.11	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	0	2.11	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.11	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.11	1	0
Sarcoma, Epithelioid [description not available]	0	2.11	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	2.11	1	0
Angiogenesis, Pathologic [description not available]	0	2.11	1	0
Blast Phase [description not available]	0	3.51	1	1
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	0	3.51	1	1
B-Cell Lymphoma [description not available]	0	2.13	1	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	2.13	1	0

rg7388

Description

Cross-References

Synonyms (53)

Research Excerpts

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (219)

Molecular Functions (61)

Ceullar Components (37)

Bioassays (50)

Research

Studies (69)

Market Indicators

Research Demand Index: 27.09

Study Types

rg7388

Description

Cross-References

Synonyms (53)

Research Excerpts

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (219)

Molecular Functions (61)

Ceullar Components (37)

Bioassays (50)

Research

Studies (69)

Market Indicators

Research Demand Index: 27.09

Study Types

Related Drugs (42)

Related Conditions (74)